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Abstract  
Words: 246 
BACKGROUND: Chronic kidney disease (CKD) is a risk factor for arrhythmias in patients with heart 
failure (HF). However, the effects of CKD on ventricular arrhythmia burden in patients with cardiac 
resynchronisation therapy and defibrillator (CRT-D) devices in a primary prevention setting are 
unknown. 
OBJECTIVE: To determine whether baseline CKD is associated with increased risk of ventricular 
arrhythmia (VA) in patients implanted with primary prevention CRT-D devices. 
METHODS and RESULTS: In this retrospective study, 199 consecutive primary prevention CRT-D 
recipients (2005-2010) were stratified by estimated glomerular filtration rate (eGFR) levels prior to 
device implantation with 106 (53.2%) ≥CKD III (eGFR <60ml/min/1.73m2) (CKD group). CKD group 
patients were significantly older (70.0±10y vs. 61.3±12y, p<0.05) with higher prevalence of ischemic 
cardiomyopathy (56.2% vs. 40.2%, p<0.05). Detected ventricular tachycardia (VT)/ventricular 
fibrillation (VF) episodes resulting in device therapy occurred significantly more frequently in the 
CKD group [40/106(37.8%)] than controls [24/93(25.8%)], (OR=1.74, 95% CI=1.01-3.2, p=0.05). At 5-
year follow up, interval censored data analysis showed 41% VT/VF incidence in the CKD group 
compared to 24% incidence in controls, (p<0.05). Cox proportional hazards model identified CKD >III 
as the only predictor of sustained VA in this group (adjusted HR 2.92, CI =1.39–6.1, p=0.004).  
CONCLUSION: Baseline CKD is a strong independent risk factor for ventricular arrhythmia in primary 
prevention CRT-D recipients. Further understanding of the underlying arrhythmogenic mechanisms 
relating to CKD may be of interest to allow appropriate correction and prevention. Device 
programming in this cohort may need to reflect this increased risk. 
 
Key-words: Cardiac resynchronisation therapy, Chronic Kidney Disease, Implantable cardioverter 
defibrillator, Heart failure, Renal failure. 
 Abbreviations: 
 
ATP – Anti-tachycardia Pacing 
CAD – Coronary artery disease 
CKD – Chronic Kidney Disease 
CRT-D – Cardiac Resynchronisation Therapy- Defibrillator 
EF – ejection fraction 
eGFR -  Estimated Glomerular Filtration rate 
EGM – electrogram 
HF – Heart Failure 
ICD – Implantable Cardioverter Defibrillator 
LV – left ventricle 
MI – Myocardial infarction 
MDRD - Modified Diet in Renal Disease  
NKF KDOQI - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
NYHA – New York Heart Association 
SCD – Sudden Cardiac Death 
VA – Ventricular Arrhythmia 
VT – Ventricular tachycardia 
VF – Ventricular Fibrillation 
  
Introduction  
Cardiac Resynchronisation Therapy (CRT) is an established adjunctive therapy in treating patients 
with heart failure (HF) with proven mortality benefit.1 It is well recognised that patients with HF and 
poor left ventricular function are at increased risk of sudden cardiac death (SCD) due to ventricular 
arrhythmia (VA).2 Therefore, many patients suitable for CRT are also candidates for primary 
prevention defibrillator therapy.3 However, these devices are also associated with possible 
complications4 and some patients may not benefit from implantable cardioverter defibrillators (ICDs) 
as they do not experience a ventricular tachycardia (VT)/ventricular fibrillation (VF) episode in their 
lifetime.5-7 Identifying individuals most likely to benefit from ICDs remains unresolved.5 
Chronic Kidney Disease (CKD) is common in congestive HF (CHF) patients. Up to 40% of patients with 
CHF have been reported to have CKD with estimated glomerular filtration rate (eGFR) 
<60mls/min/1.73m2, as found in the ANCHOR (Anaemia in chronic heart failure: Outcomes and 
Resource Utilization) registry.8 CKD is a powerful independent predictor of fatal and non-fatal 
adverse cardiovascular outcomes in patients post-myocardial infarction (MI), as well as in patients 
with CHF, with both preserved or reduced left ventricular ejection fraction (LVEF).9-12 A recent meta-
analysis found an incremental 7% 1-year mortality rate for every 10ml/min decrease in eGFR in 
patients with renal impairment and HF.13 
Cardiac resynchronisation therapy (CRT), through its long term reverse remodelling effects on the 
left ventricle, is known to decrease the incidence of sudden cardiac death (SCD) due to ventricular 
arrhythmia in CHF patients.1;3 Therefore, pathological processes negatively impacting reverse 
remodelling are likely to diminish the protective effect of CRT on SCD. A sub-group analysis of 
“resynchronization reverses remodelling in Systolic Left ventricular dysfunction” (REVERSE) study 
showed CKD patients with CRT had significantly less improvement in reverse remodelling parameters 
compared to those with normal renal function.14 We hypothesise that the incidence of sustained 
ventricular arrhythmia among CHF patients receiving CRT therapy is likely to be higher in patients 
with renal impairment. Retrospective analysis of device data in patients receiving CRT-D therapy in 
the primary prevention setting was performed to determine whether baseline renal impairment has 
an independent effect on ventricular arrhythmic burden.  
 
Methods 
Consecutive patients receiving CRT-D therapy from January 2005 to December 2010 at our centre 
were identified through computerised databases. A total of 442 patients underwent CRT-D 
implantation during this period. Of these, 160 (36.2%) underwent CRT-D implantation for secondary 
prevention purposes and were excluded. Patients receiving CRT-D devices in the context of 
hypertrophic cardiomyopathy and congenital heart disease were excluded from further analysis to 
avoid confounding results due to the different ventricular arrhythmia burden and substrates in these 
special groups. Patients with LVEF >35% on transthoracic echocardiography prior to CRT-D device 
implantation were also excluded from further analysis, as were patients in whom LV lead insertion 
was unsuccessful to preserve homogeneity in comparative groups. The remaining 199 CHF patients 
who underwent CRT-D for primary prevention comprised the study population (Figure 1). Data were 
extracted with respect to baseline patient demographics, LVEF, New York Heart Association (NYHA) 
class, anti-arrhythmic medications, baseline serum creatinine and eGFR at the time of device 
implantation.  
The study cohort was categorised into 2 groups based on baseline eGFR: CKD group (patients with 
eGFR <60ml/min/1.73m2) and the Control group (patients with eGFR >60 ml/min/1.73m2). The eGFR 
was calculated using the Modified Diet in Renal Disease (MDRD) formula:  eGFR (mL/min/1.73m2) = 
175x [serum creatinine (μmol/L)x0.0113]-1.154 x age(years)-0.203 (x 0.742 if female)15  
In patients identified to have eGFR <60 ml/min/1.73m2, past eGFR measurements over 6 months 
were ascertained, to determine that low eGFR was indeed a true reflection of CKD and not acute 
renal impairment. An eGFR <60ml/min/1.73 m2 denotes the presence of at-least moderate renal 
impairment, and defined as CKD stage 3, according to The National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF KDOQI) guidelines. In addition, population based studies 
have shown that CKD stage 3 is associated with twice the risk of sudden cardiac death (SCD) in 
patients with renal impairment.16 Therefore eGFR <60ml/min was selected as the cut-off to define 
CKD stage 3 in the present study. To corroborate this, we also assessed the optimal cut-off for eGFR 
in our sample using a ROC curve to obtain the Youden index (best combination of specificity and 
sensitivity) in determining the ventricular arrhythmic burden.  
Data from device clinic follow-up records and stored device electrograms (EGMs) during episodes of 
detected VT/VF and therapy deliveries were retrospectively analysed for at least 5 years in all 
surviving patients. Therapy delivery was defined as either anti-tachycardia pacing (ATP) or 
appropriate ICD shocks for ventricular arrhythmia. Detected ventricular arrhythmia episodes were 
classified as either 1) Non-sustained VT (NSVT) - defined as ventricular tachycardia meeting 
detection criteria that terminated spontaneously without therapy delivery or 2) VT/VF defined as 
ventricular sustained tachyarrhythmia meeting detection criteria that resulted in therapy delivery. 
VT episodes which met detection criteria but terminated before re-confirmation were classified as 
NSVT. Therapies delivered due to inappropriate tachycardia detections (for supra-ventricular 
tachycardia, sinus tachycardia, sensing failure or artefact and determined by analysis of stored EGMs 
for each episode) were not included for analysis. Although data regarding multiple shocks/therapies 
in a single patient were collected and incidences compared, for the purpose of time to event 
analysis, only time to first event was considered (Kaplan-Meier analysis and Cox Regression). 
Patients were censored after the first sustained ventricular arrhythmia needing therapy. Mortality 
data (all cause mortality) were collected through computerised databases, hospital records and by 
collecting data through patients’ registered general practitioners in those lost to hospital/device 
clinic follow-up. 
 Tachycardia detection criteria were altered in some patients during the analysis period to allow 
optimal arrhythmia management following VA episodes, and for patients with lead advisories or 
those in whom artefact had been recorded on the right ventricular pace-sense component, or 
patients with frequent but more prolonged episodes of NSVT leading to ATP. Permission to 
retrospectively review medical records for this analysis was obtained from the local ethics 
committee. 
Statistical analysis 
Categorical variables in each group are presented as percentages and continuous variables as mean 
(±SD) and/or median (interquartile range) where appropriate. Categorical variables were compared 
by the X2 test. Continuous variables were compared by Student’s t-test. Kaplan-Meier analysis was 
performed to estimate freedom from VT/VF and the log rank test was used for time to event 
comparison. Cox proportional hazards (Forward stepwise conditional method; probability for 
stepwise= 0.05) was used to evaluate the effects of co-variates in the time to event analysis. A p-
value <0.05 was considered statistically significant. Statistical analysis was performed using the 
statistical software SPSS version 15 (SPSS Inc., Chicago, IL, USA). 
There are no previous studies assessing the incidence of VT/VF in a cohort of CKD patients with CRT-
D and, therefore, an exploratory study with no previous power assessment to document an 
association between CKD and VT/VF in this population was performed. 
Results  
Baseline characteristics 
A total of 199 patients underwent CRT-D device implantation for primary prevention between 
January 2005 and December 2010 (Figure 1). Mean age was 66.05+12.1 years and 54 (27.1%) were 
female. 106 patients (53.3%) had an eGFR <60mls/min/1.73m2 (CKD group) immediately prior to the 
implant and the remaining 93 patients (46.7%) constituted the control group. 
Baseline characteristics in the two groups are shown in Table 1. Both groups were similar with 
respect to sex distribution, baseline LVEF, baseline QRS duration and use of medications - including 
ACE inhibitors, beta-blockers and amiodarone at the time of device implantation. CKD group patients 
were older (70.06±10 yrs vs. 61.3±12 yrs p <0.01), had a higher proportion of ischemic 
cardiomyopathy (56.2% vs. 40.2% p <0.05) and a higher prevalence of AF at the time of implantation 
(36.7% vs. 18.3%, p<0.05). 
Device programming 
The distribution of device manufacturers were Boston Scientific (60%), Medtronic (21%), St Jude 
(17%) and Biotronik (1%). Although all devices were for primary prevention purposes, most were 
programmed with two therapy zones, reflecting practice during the time period of 2005-2010. In 
general, a VT zone for ventricular rates >171 bpm with detection requiring approximately 2.5–9.0s 
(depending on manufacturer) and a VF zone for ventricular rates >210 bpm, with detection requiring 
approximately 1.0s–5.0s (depending on manufacturer) summarises device programming in the study 
cohort. There was no difference in the biventricular pacing percentage between the two groups 
(94.4% vs 96.1% (CKD vs control) group, p= 0.84) 
 
Incidence of Ventricular Tachyarrhythmia  
Mean follow up duration was longer in the control group (55.5+30 vs. 44.2+28 months, p=0.007). 
The exact incidence and interval censored incidence of ventricular arrhythmia were calculated. 
VT/VF requiring device therapy occurred significantly more frequently in the CKD group 
40/106(37.8%) than controls 24/93(25.8%), (OR=1.74, 95% CI=1.01-3.2, p=0.05). At 5-year follow up, 
an interval censored data analysis showed 41% VT/VF incidence in the CKD group compared to 24% 
incidence in controls (Figure 2, p<0.05). ROC Curve analysis for VT/VF occurrence and eGFR values, 
identified an e-GFR of 59.5 ml/min as the optimal cut-off point (Youden index).  
Incidence of recurrent VTs (≥2 VT/VF episodes requiring therapy) was observed in 15/106 (14.2%) 
patients in the CKD group and 10/93 (10.8%) in the control group, but did not achieve statistical 
significance (OR=1.19, CI=0.79-1.97, p=0.52).  
Inappropriate therapies occurred in 6.1% of patients (12). There was no difference in the incidence 
of inappropriate therapy in the two groups, CKD group 5.7% vs 6.5% in the control group, p=0.96. 
Kaplan-Meier survival curves (Figure 3) showed a higher incidence of first sustained VT/VF over time 
in CKD patients (p=0.003, HR=2.034, 95%CI 1.22-3.39). By 5 years follow-up 41% of patients in the 
CKD group experienced appropriate ICD interventions for sustained VA (Figure 3), compared with 
only 24% in the control group. Based on these figures, the calculated number needed to treat (NNT) 
for CKD patients undergoing ICD implantation to receive an appropriate ICD therapy is 5.9.  
Predictors of VT/VF 
On univariate Cox regression, male sex (HR=1.90 95%CI=1.02-3.5, p=0.04), baseline LVEF (HR=0.96, 
95%CI=0.93-1.0, p=0.051) and CKD stage >III (HR=2.034, 95%CI=1.22-3.39, p=0.007) were 
independent predictors of a first VT/VF event. However, multivariate Cox regression identified CKD 
stage >III as the only independent predictor of sustained VA occurrence in this cohort (HR=2.05, 
95%CI=1.14-3.68, p=0.016). Age, gender, baseline LVEF, etiology of HF (ischemic vs. non-ischemic), 
use of ACE-inhibitors, beta-blockers and amiodarone were not found to be independent risk factors 
using this multivariate model.   
Mortality data 
During the follow-up period, 82 deaths were recorded, implying an overall 41.2% mortality in this 
cohort. The mortality rate was significantly higher in the CKD group compared to the control group, 
47.2% vs 34.4%, OR 1.336, 95%CI=0.97-1.84, p=0.06). Kaplan-Meier survival curves (Figure 4) 
showed significant differences in mortality, with increased overall mortality in the CKD group, log 
rank 5.15, p=0.023. Survival rates at 1,2, and 5 years in two groups were 93%, 90% and 68% in 
control group and were 94%,86% and 57% in CKD group.  However, a Cox proportional hazards 
model did not identify CKD as an independent predictor for mortality. None of the covariates 
showed significance in Cox proportional hazard modelling for mortality, with male sex closest to 
significance (Table 3).  
 
Discussion  
 
Results from the present study demonstrate that baseline renal impairment is an independent 
predictor of sustained ventricular arrhythmia necessitating ICD therapies in patients with CRT-D 
devices implanted for primary prevention. 
CKD is an established independent risk factor for all cause mortality, even in non-dialysis dependent 
patients,17 and the incidence of cardiovascular disease is very common in this cohort, which has also 
been found to be the commonest mode of death in population based studies.18-20 Significant 
proportions of patients with CKD suffer sudden cardiac death, unrelated to atherosclerotic events or 
heart failure, suggesting different pathophysiologies play a role.21 The finding of increased incidence 
of malignant ventricular arrhythmias in HF patients with CKD in patients with CRT devices in the 
present study may imply greater vulnerability to arrhythmia in the general heart failure population 
with concomitant CKD and merits further study. In a recent retrospective study of patients 
undergoing primary prevention ICD implantation, it was shown that CKD was an independent 
predictor of appropriate ICD therapies.22  
Despite ICD implantation, CKD patients have significantly poorer prognosis due to multiple factors, 
including worsening HF due to CKD, progression of coronary artery disease (CAD) due to 
hypercalcaemia and increased inflammation, advanced age at presentation and the effects of 
chronic anaemia.23-25 In the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) study, 
which examined ICD placement versus medical therapy in CHF patients, serum creatinine was found 
to be an independent predictor of time to first appropriate ICD shock or therapy.26 In a post-hoc 
subgroup analysis of MADIT II trial each 10 ml/min/1.73 m2 reduction in eGFR increased the risk of 
all-cause mortality and SCD by 16% (p=0.005) and 17% (p = 0.03), respectively.27 However, those 
patients with more advanced renal failure have a greater propensity for non-arrhythmic modes of 
death, implying a dynamic arrhythmic substrate with disease progression.28 These findings have, as a 
consequence, led to the development of decision models for implantation of primary prevention 
ICDs in CKD patients.29  
In contrast to the studies involving CKD patients undergoing ICD implantation, the outcomes of CKD 
patients undergoing CRT implantation has not shown compelling evidence of poor prognosis when 
compared to patients with normal renal function. Sub-group analyses of CARE-HF, RAFT and 
REVERSE studies showed no difference in the primary outcomes in patients with CKD compared to 
patients without.30-32 However, a sub-group analysis of the COMPANION trial showed a significant 
increase in SCD in patients with CKD (HR: 1.69; 95% CI: 1.06 to 2.69; p =0.03).33 None of these 
randomised studies were sufficiently powered to assess the impact of renal function and outcomes 
and, consequently, no clear recommendations are available for CKD patients regarding benefit of 
CRT, nor decision models developed. Results from the present study suggest that in HF patients with 
CRT-D devices implanted for primary prevention, a higher arrhythmic burden is found in CKD 
patients. 
Putative role of renal dysfunction in risk of ventricular arrhythmia 
Structural and electrophysiological remodelling of the heart, vascular calcification and fibrosis, 
autonomic dysregulation, and volume and electrolyte shifts are some of the underlying processes 
thought to explain the increased predisposition for SCD in people with CKD.25 
A sustained ventricular arrhythmia requires interplay between two important factors. Firstly, a 
transient event (or a trigger) and secondly an underlying myocardial substrate which poses an 
electrical instability for ventricular arrhythmia to be sustained.25 Adverse cardiac remodeling that 
includes left ventricular hypertrophy and fibrosis in CKD patients is described in many studies and 
this is possibly the most important mechanism through which the myocardial substrate becomes 
vulnerable to VA.34-38 Commonly associated co-morbidities in CKD patients, i.e diabetes mellitus, 
hypertension and anaemia partly contribute to adverse left ventricular remodeling.39;40 The 
molecular basis for these changes includes activation of growth factors, proto-oncogenes, plasma 
noradrenalin, cytokines, and angiotensin II. These factors regulate intracellular processes that 
accelerate cardiac hypertrophy, myocardial fibrosis, and apoptosis.25;41;42 Both left ventricular 
hypertrophy and cardiac fibrosis have been implicated in increasing the risk for sustained ventricular 
arrhythmias and the predisposition to SCD.38;43 Structural changes can alter the electrophysiological 
properties of the myocardium. Fibrosis disrupts the normal myocardial architecture and results in a 
slowing of conduction velocity across the diseased tissue.25 This pathology can form heterogeneous 
zones of conduction and repolarization that can sustain a re-entrant arrhythmia such as ventricular 
tachycardia.44-46 Cardiac fibrosis and left ventricular hypertrophy have been implicated in various 
studies to cause early after depolarisations, which acts as a trigger in inducing ventricular 
arrhythmias.47;48  Sympathetic hyperactivity is a well established phenomenon occurring in patients 
with renal impairment.49;50 A decreased beta blockade effect in patients with renal impairment has 
been demonstrated and certainly could contribute to increased the ventricular arrhythmia observed 
when compared to patients without renal dysfunction.51 Plasma norephinephrine levels in CKD 
patients is also linked with higher incidence of all cause cardiovascular mortality.52 Various 
electrolyte abnormalities observed in renal dysfunction, including hyperkalemia, uremia, and 
metabolic acidosis contribute to a pro-arrhythmic state in these patients, however, this is more 
often observed in end stage CKD patients dependent on hemo-dialysis.24 In patients with advanced 
renal disease needing hemo-dialysis, ventricular repolarization heterogeneity manifested by 
increased QT dispersion is another reason to develop malignant arrhythmias.53  
In the current study, patients with severe CKD (e-GFR <30) were only a minority (n = 3). Two of these 
3 patients (66%) developed sustained VT/VF during follow up compared to 20.5% of patients with e-
GFR >30. However, owing to the very small number of these patients in our study, statistical 
significance was not reached. 
 
Conclusions 
Baseline CKD is a strong independent predictor for ventricular arrhythmia in primary prevention 
CRT-D recipients in this retrospective, single-centre analysis. Further understanding of the 
underlying arrhythmogenic mechanisms in CKD may be of interest to allow a better treatment and 
prevention approach of dysrhythmia in this subset of patients. >50% of patients with primary 
prevention CRT-D devices have CKD and CKD is an independent risk factor for developing ventricular 
arrhythmia resulting in device therapy in this study. The presence of CKD, however, does not 
influence mortality. Results suggest the presence of CKD should be incorporated into decision 
models for identifying patients with LV dysfunction likely to benefit from device therapy and used to 
identify those at greater risk of receiving ICD therapies after implant. 
 
Limitations    
There are several limitations to this study. The study cohort was small and retrospectively analysed 
and based on data from only a single centre. Patients in the CKD Group were significantly older than 
those in the Control Group. However, this difference was adjusted in a Cox proportional hazard 
model, which did not identify age as an independent predictor for sustained ventricular arrhythmia. 
Not surprisingly, patients in the CKD Group had a higher proportion of ischaemic cardiomyopathy 
than the Control Group and CKD is well known to be associated with increased risk of atherosclerotic 
disease, independent of other traditional risk factors.54 In the multivariate Cox proportional hazards 
model, this aetiology was not an independent predictor of sustained arrhythmia thereby highlighting 
that, apart from accelerated CAD, other pathophysiological processes have a role in risk for 
ventricular arrhythmia.21;25 In addition, as with all retrospective analyses of patients with cardiac 
rhythm devices, there are differences in device programming between patients. Although most 
patients were programmed with similar primary prevention device settings for detection of 
treatment of ventricular arrhythmias, 12% of patients who had not exeperienced therapies since 
implant were reprogrammed with long detection criteria from the year  2013 onwards in light of the 
results of the MADIT-RIT trial.55 Therefore, the incidence of treated ventricular arrhythmias is likely 
to have decreased from the latter part of 2013 onwards, although this reflects real-world practice 
and both groups would likely have been similarly affected. 
 
 
 
  
Figure 1.  Consort diagram showing the study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: HCM- Hypertrophic Cardiomyopathy 
LV lead- Left ventricular lead  
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Table 1 – Comparison of baseline characteristics 
Legend: 
eGFR – estimated glomerular filtration rate (ml/min);  
NYHA – New York Heart Association functional class; 
LVEF – left ventricular ejection fraction;  
ACE – angiotensin converting enzyme 
 
 
 Group 1 (eGFR <60) 
n=106 
Group2 (eGFR ≥60ml/min) 
n=93 
P 
Mean Age 70.06 62 <.05 
Male 75% 70% NS 
NYHA median 
mean 
3 
2.67 
3 
2.46 
NS 
Mean LVEF 24.8% 25.0% NS 
Mean QRS width (ms) 141 146 NS 
AF prevalence 36.7% 18.3% <.05 
Ischemic 
cardiomyopathy 
56.2% 40.2% <.05 
Amiodarone 13.3% 7.8 NS 
Beta Blocker 77% 81% NS 
ACE inhibitor 91% 94% NS 
 Figure 2. Interval censored Incidence of sustained VT/VF at 5 yrs after device implantation  
 
 
 
Legend: VT – ventricular tachycardia; VF – ventricular fibrillation. eGFR – estimated glomerular 
filtration rate (ml/min). 
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Figure 3. Kaplan-Meier curve: Freedom from Sustained VT/VF  
 Legend: VT – ventricular tachycardia; VF – ventricular fibrillation; CKD  - chronic kidney disease. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: CI – confidence interval; HR – hazard ratio; LL – lower limit; UL – upper limit; CKD – chronic 
kidney disease; ACE – angiotensin converting enzyme; LVEF – left ventricular ejection fraction; 
NYHA – New York Heart Association functional class. 
 
 
 
 
 
 
 
Table 2.  Univariate and multivariate cox regression model of VT/VF 
occurence. 
 
 
Univariate analysis 
               95% CI 
 
Multivariate analysis 
                    95%  CI 
 
Variable HR LL UL p HR LL UL P 
Sex 1.901 1.029 3.514 .040 - - - NS 
CKD 2.034 1.219 3.394 .007 2.924 1.399 6.109 .004 
Amiodarone - - - NS - - - NS 
Beta 
blocker 
- - - NS - - - NS 
ACE 
inhibitor 
- - - NS - - - NS 
Age - - - NS - - - NS 
Mean LV EF 0.966 0.933 1.0 .051 - - - NS 
NYHA - - - NS - - - NS 
Etiology 1.673 1.011 2.768 0.045 - - - NS 
Figure 4.  Kaplan Meier Curve- All cause mortality 
 
 
Legend: CKD – chronic kidney disease.
Table 3  Univariate and multivariate cox regression model of Mortality. 
 
 
 
 
 
 
 
 
 
 
 
Legend: CI – confidence interval; HR – hazard ratio; LL – lower limit; UL – upper limit; CKD – chronic kidney dsease; 
ACE – angiotensin converting enzyme; LVEF – left ventricular ejection fraction; NYHA – New York Heart Association 
functional class. 
 
 
 
 
 
 
 
 
Univariate analysis 
               95% CI 
 
Multivariate analysis 
                    95%  CI 
 
Variable HR LL UL p HR LL UL p 
Sex 1.980 1.128 3.475 .017 1.905 0.907 4.001 .08 
CKD 1.663 1.064 2.598 .026 - - - NS 
Amiodarone - - - NS - - - NS 
Beta    
blocker 
- - - NS - - - NS 
ACE 
inhibitor 
- - - NS - - - NS 
Age 1.032 1.011 1.053 .003 - - - NS 
Mean LVEF - - - NS - - - NS 
NYHA 1.579 1.110 2.246 0.011 - - - NS 
Etiology - - - NS - - - NS 
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